A Quantitative Efflux Ratio-Integrated Model for Passive Permeability Estimation from Caco-2 Assays.

Area of Science:

• Pharmacology
• Drug Discovery
• Biotechnology

Background:

• Estimating passive permeability is crucial for drug discovery but challenging due to active efflux in Caco-2 assays.
• Current methods often require complex, costly additional experiments.

Purpose of the Study:

• Develop a quantitative method to directly estimate passive permeability from standard Caco-2 assay data.
• Eliminate the need for additional experimental systems.

Main Methods:

• Developed the empirical Efflux Ratio Integrated Model (ERIM).
• Incorporated Efflux Ratio (ER) into a correction framework for bidirectional apparent permeability data.
• Validated the model using 138 compounds and compared it with the Global Average Model (GAM).

Main Results:

• The Global Average Model (GAM) systematically overestimated passive permeability, increasing with Efflux Ratio (ER), leading to high false-positive rates.
• ERIM effectively eliminated efflux-dependent bias and significantly reduced false-positive classifications.
• ERIM maintained low false-negative rates and demonstrated consistent performance across validation rounds.

Conclusions:

• The Efflux Ratio Integrated Model (ERIM) offers a straightforward and practical method for estimating passive permeability from single Caco-2 assays.
• ERIM corrects for efflux-related bias, enhancing data interpretability.
• This approach supports more efficient compound prioritization in early-stage drug discovery.